Graham P. Collins
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 99
- Genetics top 1%
- Chronic Lymphocytic Leukemia Research 50
- Oncology top 2%
- CAR-T cell therapy research 40
- Viral-associated cancers and disorders 21
- Cancer Immunotherapy and Biomarkers 13
- Neurology top 2%
- CNS Lymphoma Diagnosis and Treatment 18
- Immunology top 5%
- T-cell and Retrovirus Studies 10
-
- Acute Lymphoblastic Leukemia research 10
- Co-authors
- Toby A. EyrePier Luigi ZinzaniStephen M. AnsellArmando SantoroKerry J. SavageJonathon B. CohenPhilippe ArmandAndreas Engert
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Graham P. Collins
151 papers receiving 2.6k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Pathology and Forensic Medicine 1.6k
- Genetics 686
- Oncology 1.6k
- Neurology 525
- Immunology 584
Countries citing papers authored by Graham P. Collins
This map shows the geographic impact of Graham P. Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Graham P. Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Graham P. Collins more than expected).
Fields of papers citing papers by Graham P. Collins
This network shows the impact of papers produced by Graham P. Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Graham P. Collins. The network helps show where Graham P. Collins may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Graham P. Collins, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 13 | |
| 3 | 2024 | 6 | |
| 4 | 2024 | 5 | |
| 5 | 2024 | 2 | |
| 6 | 2024 | 0 | |
| 7 | 2023 | 4 | |
| 8 | 2023 | 13 | |
| 9 | 2021 | 17 | |
| 10 | 2020 | 14 | |
| 11 | 2020 | 25 | |
| 12 | 2020 | 58 | |
| 13 | Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trialbreakdown → | 2018 | 455 |
| 14 | 2018 | 144 | |
| 15 | 2018 | 17 | |
| 16 | 2018 | 35 | |
| 17 | 2018 | 7 | |
| 18 | 2017 | 2 | |
| 19 | Immunochemotherapy With Obinutuzumab Or Rituximab In Previously Untreated Follicular Lymphoma In The Randomized Phase III Gallium Study: Analysis By Chemotherapy Regimen | 2017 | 1 |
| 20 | 2013 | 3 |
About Graham P. Collins
Graham P. Collins is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology, having authored 160 papers that have together received 2.7k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (99 papers), Chronic Lymphocytic Leukemia Research (50 papers), CAR-T cell therapy research (40 papers), Viral-associated cancers and disorders (21 papers), CNS Lymphoma Diagnosis and Treatment (18 papers), Cancer Immunotherapy and Biomarkers (13 papers), T-cell and Retrovirus Studies (10 papers) and Acute Lymphoblastic Leukemia research (10 papers). The work is most often cited by research in Pathology and Forensic Medicine (1.6k citations), Genetics (686 citations) and Oncology (1.6k citations). Graham P. Collins has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Toby A. Eyre, Pier Luigi Zinzani, Stephen M. Ansell, Armando Santoro, Kerry J. Savage, Jonathon B. Cohen, Philippe Armand, Andreas Engert, Anas Younes and Margaret A. Shipp.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.